LY249933: a cardioselective 1,4-dihydropyridine with positive inotropic activity.

Abstract:

:Compound LY249933 and its component diastereomers, (RR) and (SR), were studied for their vascular and cardiac effects in vitro and in vivo. In guinea pig cardiac ventricular membranes, LY249933, (RR), and (SR) potently displaced bound [3H]nitrendipine (Kd values = 2-6 nM). In isolated guinea pig right ventricular strips, LY249933 produced a small but significant increase in contraction, whereas (RR) substantially increased (-log EC50 (M) = 4.6 +/- 0.8) and (SR) decreased contraction (-log EC50 (M) = 4.1 +/- 0.8). In isolated canine cephalic vein, contracted with 80 mM KCl, an increase in contraction was produced by (RR), whereas relaxation was produced by LY249933 (-log EC50 (M) = 5.9 +/- 0.9) and (SR) (-log EC50 (M) = 6.0 +/- 0.7). At 20 mM KCl, (RR) increased, (SR) decreased, but LY249933 did not alter contraction. In anesthetized dogs, LY249933 (200 micrograms/kg/min, i.v.) increased dP/dt60, decreased heart rate, but did not change vascular resistance or rate pressure product. At the same dose, (RR) and (SR) both tended to increase dP/dt60 nonsignificantly, whereas (RR) increased and (SR) decreased vascular resistance. Both (RR) and (SR) tended to decrease heart rate nonsignificantly, whereas (RR) did not change and (SR) decreased rate pressure product. Thus, LY249933 produced potentially beneficial cardiovascular changes resulting from the combined actions of its (RR) and (SR) diastereomers that are postulated to be calcium agonist and antagonist, respectively.

journal_name

J Cardiovasc Pharmacol

authors

Holland DR,Wikel JH,Kauffman RF,Smallwood JK,Zimmerman KM,Utterback BG,Turk JA,Steinberg MI

subject

Has Abstract

pub_date

1989-09-01 00:00:00

pages

483-91

issue

3

eissn

0160-2446

issn

1533-4023

journal_volume

14

pub_type

杂志文章
  • Biologics and Cardiovascular Disease.

    abstract::The advent of biologic therapy has enhanced our ability to augment disease in an increasingly targeted manner. The use of biologics in cardiovascular disease (CVD) has steadily increased over the past several decades. Much of the early data on biologics and CVD were derived from their use in rheumatologic populations....

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0000000000000595

    authors: Van Taunay JS,Albelda MT,Frias JC,Lipinski MJ

    更新日期:2018-08-01 00:00:00

  • Diet and the role of lipoproteins, lipases, and thyroid hormones in coronary lesion growth.

    abstract::Relationships between lipoprotein fractions, lipoprotein lipase activities, thyroid hormones, and coronary lesion growth were studied among 35 male patients with severe coronary atherosclerosis, who had participated in the Leiden Intervention Trial, a lipid-lowering dietary intervention program. Coronary arteriography...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Barth JD,Jansen H,Kromhout D,Reiber JH,Birkenhäger JC,Arntzenius AC

    更新日期:1987-01-01 00:00:00

  • Effects of histamine on porcine isolated myocardium: differentiation from effects on human tissue.

    abstract::Inotropic effects of histamine have been studied extensively in many species, but data on porcine myocardium, often used as a model for human heart, are not available. We investigated inotropic effects of histamine on atrial and ventricular trabeculae obtained from porcine hearts. For comparison, we also evaluated the...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199309000-00019

    authors: Du XY,Schoemaker RG,X462P6,Bos E,Saxena PR

    更新日期:1993-09-01 00:00:00

  • Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.

    abstract::Diabetes and CYP2C19 loss of function (LOF) alleles are associated with the variable antiplatelet activity of the prodrug clopidogrel. We conducted a randomized trial (NCT03613857) to compare the combined and individualized effects of diabetes and CYP2C19 polymorphisms on the antiplatelet reactivity of clopidogrel ver...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000881

    authors: Mohareb MW,AbdElghany M,Zaki HF,El-Abhar HS

    更新日期:2020-10-01 00:00:00

  • The long-term exposure of endothelial cells to molsidomine increases their antithrombogenicity by inducing the production of nitric oxide-related chemical substances.

    abstract::Long-term exposure of endothelial cells to molsidomine in vivo and in vitro improves the thromboresistance of endothelial cells, judging from the inhibition of platelet aggregation by endothelial cells in autologous plasma. In cultured endothelial cells, the present studies attempted (a) to show that platelets influen...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Berenger-Bahuet FP,Rolland PH

    更新日期:1989-01-01 00:00:00

  • The Impact of Novel Anticoagulants: Should All AF Patients Now Be Anticoagulated?

    abstract::Atrial Fibrillation (AF) is accompanied by an increased risk for thromboembolic events in most affected patients. Current guidelines therefore recommend antithrombotic therapy with vitamin K antagonist (VKA) or non VKA oral anticoagulant (NOAC) in the majority of AF patients. Current AF treatment guidelines recommend ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0000000000000297

    authors: Hammwöhner M,Goette A

    更新日期:2015-12-01 00:00:00

  • Effects of the converting enzyme inhibitor quinapril (CI-906) on blood pressure, renin-angiotensin system, and prostanoids in essential hypertension.

    abstract::Fourteen patients with mild to moderate essential hypertension were randomized, after a baseline placebo period of 4 weeks, to receive the angiotensin converting enzyme (ACE) inhibitor quinapril or a placebo. During a 12 week, double-blind phase, the dosage of quinapril was increased from 10 to 40 mg twice daily being...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-198807000-00012

    authors: Säynävälammi P,Pörsti I,Pörsti P,Nurmi AK,Seppälä E,Manninen V,Vapaatalo H

    更新日期:1988-07-01 00:00:00

  • Peripheral alpha 2 adrenoceptor stimulation contributes to the sympatholytic effect of guanfacine in humans.

    abstract::Guanfacine 3 mg was infused into six volunteers over 1 h on two occasions to investigate whether its sympatholytic effect is centrally or peripherally mediated. On one occasion, the central effects of guanfacine were blocked by prior administration of idazoxan 0.2 mg/kg i.v. (45 min preguanfacine); central alpha 2-blo...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-198500076-00027

    authors: Brown MJ,Struthers AD,di Silvio L

    更新日期:1985-01-01 00:00:00

  • Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance.

    abstract::Insulin resistance is associated with endothelial dysfunction and increased production of the pro-inflammatory vasoconstrictor peptide endothelin-1 (ET-1). The aim of this study was to test the hypothesis that blockade of ET receptors results in enhanced endothelium-dependent vasodilatation (EDV) in individuals with i...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/01.fjc.0000210070.47205.16

    authors: Shemyakin A,Böhm F,Wagner H,Efendic S,Båvenholm P,Pernow J

    更新日期:2006-03-01 00:00:00

  • Optimization of beta-blockers' pharmacology.

    abstract::Beta-adrenergic-blocking drugs (BABs) have a firm place in the therapy of cardiovascular conditions including angina and hypertension. Although all BABs are competitive inhibitors of beta-receptors, they may differ in their additional pharmacodynamics, i.e., beta1-(cardio)selectivity, partial agonistic activity (PAA),...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Tamargo J,Delpón E

    更新日期:1990-01-01 00:00:00

  • Is the renal natriuretic peptide urodilatin involved in the regulation of natriuresis?

    abstract::Recent evidence has shown that the kidneys produce and secrete a member of the atrial natriuretic peptide family, named urodilatin. This 32-amino acid peptide does not circulate in blood, but is secreted into urine. Urodilatin excretion closely parallels renal sodium excretion under various conditions that influence b...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/00005344-199322002-00028

    authors: Gerzer R,Drummer C

    更新日期:1993-01-01 00:00:00

  • HDL metabolism and atherosclerosis.

    abstract::Epidemiologic studies of recent years have demonstrated an association between low plasma high-density lipoprotein (HDL) cholesterol levels and the development of atherosclerosis. The PROCAM (Prospective Cardiovascular Münster) study has identified HDL cholesterol as the single parameter predictor with the highest pot...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Assmann G,Funke H

    更新日期:1990-01-01 00:00:00

  • The renal response to diltiazem and nifedipine: comparison with nitroprusside.

    abstract::We undertook a systematic comparison of the effects of diltiazem and nifedipine and a nonspecific vasodilator, sodium nitroprusside, on renal perfusion, function, and activation of potentially relevant neurohormonal systems in the anesthetized dog. These agents were employed to reduce blood pressure to two levels, a m...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198601000-00006

    authors: Blackshear JL,Orlandi C,Williams GH,Hollenberg NK

    更新日期:1986-01-01 00:00:00

  • Characterization of the endothelin receptor subtypes in human prostate.

    abstract::Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ET(A)/ET(B)) nonselective antagonist] competed for [125I]ET-1 binding with a monophasic curve. On the other hand, LU13525...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200036051-00074

    authors: Hiraoka Y,Oshita M,Morikawa K,Nagata O,Hahn KJ,Hahn A,Okada K,Taniguchi T,Muramatsu I

    更新日期:2000-11-01 00:00:00

  • Beneficial effects of a new prostacyclin analogue, KP-10614, on acute myocardial infarction in rats.

    abstract::The potential therapeutic value of a new prostacyclin analogue, (4z, 16s)-4,5,18,18,19,19-hexadehydro-16,20-dimethyl-delta 6(9a)- 9-(O)-methano-PGI1 (KP-10614), was studied in acute myocardial infarction in rats. Myocardial infarction was induced by ligation of the left coronary artery and ischemic injury was followed...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199210000-00017

    authors: Kanayama T,Kimura Y,Tamao Y,Mizogami S

    更新日期:1992-10-01 00:00:00

  • Distinct roles of second and third intracellular loops of human endothelin receptors in the selective activation of G alpha s/G alpha i.

    abstract::Endothelin-1 (ET-1) stimulated cAMP formation in Chinese hamster ovary cells stably expressing human wild-type ET(A) (CHO/hET(A) cells) and inhibited the formation in cells expressing human wild-type ETB (CHO/hETB cells), suggesting a selective coupling of hET(A) and hETB with G alpha s and G alpha i, respectively. To...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:

    authors: Ninomiya H,Takagi Y,Miwa S,Masaki T

    更新日期:1995-01-01 00:00:00

  • Metoprolol and Nebivolol Prevent the Decline of the Redox Status of Low-Molecular-Weight Aminothiols in Blood Plasma of Rats During Acute Cerebral Ischemia.

    abstract::Cerebral ischemia has previously been shown to cause a systemic decrease in levels of the reduced forms of low-molecular-weight aminothiols [cysteine (Cys), homocysteine (Hcy), and glutathione (GSH)] in blood plasma. In this study, we examined the effect of beta-adrenergic receptor (β-AR) antagonists metoprolol (Met) ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0000000000000616

    authors: Ivanov AV,Alexandrin VV,Paltsyn AA,Virus ED,Nikiforova KA,Bulgakova PO,Sviridkina NB,Svetlana Alexandrovna Apollonova,Kubatiev AA

    更新日期:2018-10-01 00:00:00

  • No evidence for a direct vasodilatory effect of celiprolol on human vasculature in vivo or in vitro.

    abstract::Celiprolol is reported to be a new cardioselective beta blocker with novel ancillary properties including vasodilator effects. The purpose of this study was to investigate whether celiprolol possesses a direct vasodilatory effect on human vasculature in vivo and in vitro. We studied the in vivo effects of intra-arteri...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198711000-00015

    authors: Hughes A,Martin G,Goldberg P,Thom S,Sever P

    更新日期:1987-11-01 00:00:00

  • NADPH oxidase inhibitors: new antihypertensive agents?

    abstract::NADPH oxidases have recently been shown to contribute to the pathogenesis of hypertension. The development of specific inhibitors of these enzymes has focused attention on their potential therapeutic use in hypertensive disease. Two of the most specific inhibitors, gp91ds-tat and apocynin, have been shown to decrease ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:10.1097/FJC.0b013e318063e820

    authors: Williams HC,Griendling KK

    更新日期:2007-07-01 00:00:00

  • Antihypertensive and metabolic effects of long-term therapy with nifedipine slow-release tablets.

    abstract::Sixteen nonhospitalized men, average age 41.3 years with essential hypertension (WHO I-II) were given nifedipine slow-release tablets of 20 mg twice daily for 48 weeks. Both supine and standing blood pressure values were significantly reduced, but heart rate was not significantly changed by the drug. A significant dec...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198501000-00003

    authors: Landmark K

    更新日期:1985-01-01 00:00:00

  • Bisoprolol improves survival in rats with heart failure.

    abstract::The cardioprotective effects of bisoprolol were studied in a rat model of severe heart failure induced by autoimmune myocarditis. Twenty-eight days after immunization, Lewis rats were divided into four groups: 0.1 mg/kg/day bisoprolol (Group 0.1), 1.0 mg/kg/day bisoprolol (Group 1) and 10 mg/kg/day bisoprolol (Group 1...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-200110001-00012

    authors: Watanabe K,Ohta Y,Inoue M,Ma M,Wahed MI,Nakazawa M,Hasegawa G,Naito M,Fuse K,Ito M,Kato K,Hanawa H,Kodama M,Aizawa Y

    更新日期:2001-10-01 00:00:00

  • Oxidation of low-density lipoprotein cholesterol following administration of poloxamer 407 to mice results from an indirect effect.

    abstract::Atherosclerosis is an inflammatory response to accumulation of cholesterol in the artery wall. Low-density lipoproteins (LDL) accumulate and are oxidized to proinflammatory compounds in the arterial intima during hypercholesterolemia, leading to activation of endothelial cells, macrophages, and T cells. We sought to d...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e318032aa11

    authors: Johnston TP,Zhou X

    更新日期:2007-04-01 00:00:00

  • Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice.

    abstract:BACKGROUND:A substantial proportion of patients with heart failure have a normal ejection fraction and diastolic dysfunction. However, there are few data available to guide the therapy of these patients. The effects of statins on cardiac remodeling are well documented in animal models and it is reported that statin the...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e31815bb629

    authors: Xu Z,Okamoto H,Akino M,Onozuka H,Matsui Y,Tsutsui H

    更新日期:2008-01-01 00:00:00

  • Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis.

    abstract::Glycogen synthase kinase (GSK)-3beta inhibitors play an anti-inflammatory role in several inflammatory diseases. Recent studies have demonstrated that GSK-3beta inhibitors protect against myocardial ischemia-reperfusion injury. However, the precise mechanisms remain unclear. We aimed to investigate the roles of inflam...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e318186a84d

    authors: Gao HK,Yin Z,Zhou N,Feng XY,Gao F,Wang HC

    更新日期:2008-09-01 00:00:00

  • Effects of terbutaline on peripheral vascular resistance and arterial compliance.

    abstract::In a double blind, randomized placebo-controlled crossover study we characterized how terbutaline affects the mean and short-term fluctuations of peripheral vascular resistance and arterial compliance. The study was carried out in six young and healthy male subjects in the supine and upright positions by recording con...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1097/00005344-200407000-00010

    authors: Kuusela TA,Jartti TT,Tahvanainen KU,Kaila TJ

    更新日期:2004-07-01 00:00:00

  • Influence of drug therapy on myocardial hypertrophy in left ventricular failure.

    abstract::The terminal phases of volume-overload heart failure are characterised by eccentric ventricular hypertrophy. Relatively little attention has been directed to exploring the mechanisms involved in this development. The increase in diastolic wall stress leads to replication of the sarcomeres in series. The hypertrophied ...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章,评审

    doi:

    authors: Taylor SH

    更新日期:1987-01-01 00:00:00

  • Platelet serotonin in essential hypertension and in mental depression.

    abstract::The similarity between the metabolic pathways of serotonin in platelets and serotoninergic nerve endings has often been emphasized. The turnover of serotonin was therefore investigated in two diseases: hypertension (as central serotoninergic neurones appear to modulate central sympathetic nervous activity) and depress...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-198500077-00003

    authors: Baudouin-Legros M,Le Quan-Bui KH,Guicheney P,Kamal LA,Meyer P

    更新日期:1985-01-01 00:00:00

  • Effects of fondaparinux and a direct factor Xa inhibitor TAK-442 on platelet-associated prothrombinase in the balloon-injured artery of rats.

    abstract::Endothelial damage triggers platelet adhesion and platelet-associated prothrombinase formation at the point of injury, resulting in the progression of thrombus formation. The present study compared the inhibitory effects of fondaparinux, an indirect factor Xa (FXa) inhibitor, and TAK-442, a direct FXa inhibitor, on pl...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/FJC.0b013e31820382a9

    authors: Konishi N,Hiroe K,Kawamura M

    更新日期:2011-02-01 00:00:00

  • Cardiovascular effects of central choline during endotoxin shock in the rat.

    abstract::The cardiovascular effects of intracerebroventricular (i.c.v.) administration of choline were studied in endotoxin-treated rats. Intravenous (i.v.) endotoxin (20 mg/kg) caused a moderate hypotension and tachycardia within 10 min of treatment. Choline (50, 100, and 150 microg; i.c.v.) increased blood pressure and decre...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/00005344-199711000-00018

    authors: Savci V,Ulus IH

    更新日期:1997-11-01 00:00:00

  • Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.

    abstract::Endothelin-1 (ET-1) is synthesized and secreted by cardiomyocytes and induces cardiac hypertrophy. Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, such as nuc...

    journal_title:Journal of cardiovascular pharmacology

    pub_type: 杂志文章

    doi:10.1097/01.fjc.0000166303.33313.01

    authors: Irukayama-Tomobe Y,Miyauchi T,Kasuya Y,Sakai S,Goto K,Yamaguchi I

    更新日期:2004-11-01 00:00:00